Literature DB >> 9690671

Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease.

H M Wisniewski1, M Sadowski, K Jakubowska-Sadowska, M Tarnawski, J Wegiel.   

Abstract

A characteristic feature of the parvopyramidal layer of the presubiculum of 6 individuals with Alzheimer disease (AD) was the presence of large, evenly distributed amyloid-beta (A beta) deposits, which in the end stage of the disease occupy 80.9 +/- 12.2% of the parvopyramidal layer. The strong reaction of A beta deposits with antibodies 4G8 (17-24 amino acids, aa), 6E10 (1-17 aa), and R165 (32-42 aa), and their weak reaction with antibody R162 (32-40 aa) indicate that potentially highly fibrillogenic A beta1-42 is a major constituent of presubicular amyloid. However, A beta deposits in the presubiculum are thioflavin-S- and Congo red-negative--and thus, nonfibrillar--even after 11 to 19 years of AD. The unique properties of presubicular amyloid appear to be related to their origin; amyloid-associated proteins such as apolipoproteins E, and AI, alpha1-antichymotrypsin, and heparan sulfate proteoglycan, which are promoters of fibrillization or stabilizers of A beta in neuritic plaques, are absent; activated astrocytes, which are the source of these proteins, are also absent. The unchanged number and distribution and the resting appearance of microglial cells revealed with RCA-I histochemistry suggest that they do not respond to diffuse A beta deposits. The source of nonfibrillar presubicular A beta is probably local neurons or neuronal projections to the parvocellular layer of the presubiculum. Neuronal, lake-like A beta deposition appears to be characteristic of AD pathology. The presubiculum is most likely the model brain structure for the study of amyloid of exclusively neuronal origin. The parvopyramidal layer of the presubiculum reveals only a small population of the neurons (2.5 +/- 2%) affected by neurofibrillary pathology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690671     DOI: 10.1097/00005072-199807000-00004

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  24 in total

1.  Links between the pathology of Alzheimer's disease and vascular dementia.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Yong-sheng Li; David Quartermain; Karen Duff; Thomas Wisniewski
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

2.  Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.

Authors:  Ayodeji A Asuni; Maitea Guridi; Joanna E Pankiewicz; Sandrine Sanchez; Martin J Sadowski
Journal:  Ann Neurol       Date:  2014-04-28       Impact factor: 10.422

3.  Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.

Authors:  Martin J Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Pankaj D Mehta; Frances Prelli; David Quartermain; Thomas Wisniewski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

4.  Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia.

Authors:  J L Holton; J Ghiso; T Lashley; A Rostagno; C J Guerin; G Gibb; H Houlden; H Ayling; L Martinian; B H Anderton; N W Wood; R Vidal; G Plant; B Frangione; T Revesz
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

5.  Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum.

Authors:  Alberto Serrano-Pozo; Jing Qian; Alona Muzikansky; Sarah E Monsell; Thomas J Montine; Matthew P Frosch; Rebecca A Betensky; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2016-04-22       Impact factor: 3.685

6.  Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.

Authors:  Alberto Serrano-Pozo; Christopher M William; Isidro Ferrer; Emmanuelle Uro-Coste; Marie-Bernadette Delisle; Claude-Alain Maurage; Christoph Hock; Roger M Nitsch; Eliezer Masliah; John H Growdon; Matthew P Frosch; Bradley T Hyman
Journal:  Brain       Date:  2010-03-31       Impact factor: 13.501

Review 7.  Amyloid-beta immunisation for Alzheimer's disease.

Authors:  Thomas Wisniewski; Uwe Konietzko
Journal:  Lancet Neurol       Date:  2008-07-28       Impact factor: 44.182

8.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration.

Authors:  Magdalena A Kuszczyk; Sandrine Sanchez; Joanna Pankiewicz; Jungsu Kim; Malgorzata Duszczyk; Maitea Guridi; Ayodeji A Asuni; Patrick M Sullivan; David M Holtzman; Martin J Sadowski
Journal:  Am J Pathol       Date:  2013-03-13       Impact factor: 4.307

10.  Automated segmentation of hippocampal subfields in drug-naïve patients with Alzheimer disease.

Authors:  H K Lim; S C Hong; W S Jung; K J Ahn; W Y Won; C Hahn; I S Kim; C U Lee
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-04       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.